Biosimilars Market based on by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook– Global Forecast up to 2032
A number of significant industry participants place a high priority on the development of biosimilars. By December 2022, 25 biosimilars had been introduced in the US and 40 had received FDA approval. FDA approvals fell off dramatically during the COVID-19 pandemic, but they resumed in 2022 with the approval of seven new biosimilars. No biosimilars were approved in 2022 citing new reference items; the seven biosimilars that were approved in 2022 all referenced products that had previously received approval as biosimilars. In addition, four additional products were introduced in 2022, including the first two biosimilar versions of Lucentis (ranibizumab). Furthermore, the FDA approved Rezvoglar (referring to Lantus (insulin glargine)) and Cimerli (referring to Lucentis (ranibizumab)) as two novel interchangeable biosimilars in 2022. The number of development programs taking part in the FDA's Biosimilar Development Program has increased even if there was a general decrease in approvals between 2020 and 2021. There were about 60–70 biosimilars undergoing pipeline research as of April 2023. (Clinical.gov); in three to four years, half of them will be introduced. Growing biosimilar approvals will provide access to a larger range of treatments and propel market expansion.
Because developing nations sometimes have laxer regulations, biosimilar firms can find substantial development prospects in the Asia Pacific, Latin America (LATAM), and Middle East markets. Their legislative processes, payer views, pricing, affordability, and competitive landscapes are different from those of established markets. Because of their cheap labor and laboratory setup costs as well as their abundance of qualified personnel, China and India are viewed as desirable locations for global biosimilar development and manufacturing companies to outsource their research and development (R&D). Important market participants have shown a great deal of interest in this.
Asia Pacific's market is a vibrant and quickly changing sector, driven by a few major firms like Dr. Reddy's Laboratories (India), Celltrion (South Korea), Samsung Bioepis (South Korea), Biocon, and Shanghai Henlius Biotech (China). These businesses have been crucial to the development and implementation of biosimilars in the area, and it is anticipated that they will continue to spur innovation and expansion in the years to come.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Biosimilars Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Biosimilars Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Biosimilars Market based on Product
The International Diabetes Federation's Atlas 2021 states that 537 million adults worldwide have diabetes, whereas the American Heart Association's data shows that the age-adjusted prevalence rate of cardiovascular disease was 7354.1 per 100,000 individuals in 2020. Over the course of the projection period, the recombinant glycosylated proteins segment is anticipated to rise at the quickest CAGR of 14.9%. Since the patents on biologics like erythropoietin (EPO), Humira, and Neulasta are about to expire, a number of companies are vying to enter the biosimilars market, which has the potential to dramatically accelerate market growth by providing patients with better access to medicines. Additionally, as a result of technological developments in the recombinant glycosylated proteins market, a number of therapeutics, including soluble receptors and modified proteins, have emerged. These developments have the potential to further propel the market's expansion.
The market has been divided into segments based on applications, including blood disorders caused by growth hormone deficiency, rheumatoid arthritis, cancer, and chronic and autoimmune disorders. Because autoimmune diseases are becoming more common and well-known, the chronic and autoimmune disorders category had the highest revenue share in 2022—roughly 21.6%. According to the National Institute of Environmental Health Sciences, autoimmune illnesses affect over 24 million people in the United States. Over the course of the forecast period, the oncology application category is anticipated to rise at the quickest CAGR of 17.0%.
Globally rising cancer cases are anticipated to be the main factor driving market expansion. As per the data disclosed by the World Cancer Research Fund International, over 18.1 million individuals were afflicted with cancer in 2020. The creation of biosimilars for cancer treatment can offer patients in low- and middle-income nations—where cancer patient mortality rates are higher—affordable therapeutic alternatives. Improving the availability of reasonably priced care can help the market grow even more.
Due to the existence of significant companies and a robust regulatory environment for biosimilars, North America dominated the market in 2022 with the biggest revenue share of 40.4%. Furthermore, biosimilars are reasonably accessible in the area. The U.S. Generic Biosimilars Saving Report 2021 states that there have been 20 biosimilars introduced and 31 approved in the country, adding up to around 10 million therapy days. The price of the 20 biosimilars that were introduced in the United States is 30% less than that of the biologics, which has led to a decrease in the cost of both biosimilars and biologics. It is anticipated that this cost reduction will give biosimilars in this area even more momentum.
Over the course of the projection period, Asia Pacific is anticipated to develop at the fastest CAGR of 18.4%. Important companies including Pfizer Inc., Celltrion, Biocon, and Dr. Reddy's Laboratories have made it easier for biosimilars to be developed and sold in this area. For example, Dr. Reddy's Laboratories introduced a biosimilar of Roche's Avastin in India in August 2019, making it easier to treat a variety of tumors. Biosimilars are predicted to rise rapidly in this region due to similar market developments and rising health care costs. The World Bank data, which was collected in April 2023, indicates that China's health expenditures as a percentage of GDP climbed from 4.98% in 2015 to 5.59% in 2020.
Because developing nations sometimes have laxer regulations, biosimilar firms can find substantial development prospects in the Asia Pacific, Latin America (LATAM), and Middle East markets. Their legislative processes, payer views, pricing, affordability, and competitive landscapes are different from those of established markets. Because of their cheap labor and laboratory setup costs as well as their abundance of qualified personnel, China and India are viewed as desirable locations for global biosimilar development and manufacturing companies to outsource their research and development (R&D). Important market participants have shown a great deal of interest in this.
Asia Pacific's market is a vibrant and quickly changing sector, driven by a few major firms like Dr. Reddy's Laboratories (India), Celltrion (South Korea), Samsung Bioepis (South Korea), Biocon, and Shanghai Henlius Biotech (China). These businesses have been crucial to the development and implementation of biosimilars in the area, and it is anticipated that they will continue to spur innovation and expansion in the years to come.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Biosimilars Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Biosimilars Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:
The segmentation coverage of the study is provided below.
Biosimilars Market based on Product
- Recombinant Non-glycosylated Proteins
- Recombinant Glycosylated Proteins
- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Rheumatoid Arthritis
- Chronic and Autoimmune Disorders
- Others
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The International Diabetes Federation's Atlas 2021 states that 537 million adults worldwide have diabetes, whereas the American Heart Association's data shows that the age-adjusted prevalence rate of cardiovascular disease was 7354.1 per 100,000 individuals in 2020. Over the course of the projection period, the recombinant glycosylated proteins segment is anticipated to rise at the quickest CAGR of 14.9%. Since the patents on biologics like erythropoietin (EPO), Humira, and Neulasta are about to expire, a number of companies are vying to enter the biosimilars market, which has the potential to dramatically accelerate market growth by providing patients with better access to medicines. Additionally, as a result of technological developments in the recombinant glycosylated proteins market, a number of therapeutics, including soluble receptors and modified proteins, have emerged. These developments have the potential to further propel the market's expansion.
The market has been divided into segments based on applications, including blood disorders caused by growth hormone deficiency, rheumatoid arthritis, cancer, and chronic and autoimmune disorders. Because autoimmune diseases are becoming more common and well-known, the chronic and autoimmune disorders category had the highest revenue share in 2022—roughly 21.6%. According to the National Institute of Environmental Health Sciences, autoimmune illnesses affect over 24 million people in the United States. Over the course of the forecast period, the oncology application category is anticipated to rise at the quickest CAGR of 17.0%.
Globally rising cancer cases are anticipated to be the main factor driving market expansion. As per the data disclosed by the World Cancer Research Fund International, over 18.1 million individuals were afflicted with cancer in 2020. The creation of biosimilars for cancer treatment can offer patients in low- and middle-income nations—where cancer patient mortality rates are higher—affordable therapeutic alternatives. Improving the availability of reasonably priced care can help the market grow even more.
Due to the existence of significant companies and a robust regulatory environment for biosimilars, North America dominated the market in 2022 with the biggest revenue share of 40.4%. Furthermore, biosimilars are reasonably accessible in the area. The U.S. Generic Biosimilars Saving Report 2021 states that there have been 20 biosimilars introduced and 31 approved in the country, adding up to around 10 million therapy days. The price of the 20 biosimilars that were introduced in the United States is 30% less than that of the biologics, which has led to a decrease in the cost of both biosimilars and biologics. It is anticipated that this cost reduction will give biosimilars in this area even more momentum.
Over the course of the projection period, Asia Pacific is anticipated to develop at the fastest CAGR of 18.4%. Important companies including Pfizer Inc., Celltrion, Biocon, and Dr. Reddy's Laboratories have made it easier for biosimilars to be developed and sold in this area. For example, Dr. Reddy's Laboratories introduced a biosimilar of Roche's Avastin in India in August 2019, making it easier to treat a variety of tumors. Biosimilars are predicted to rise rapidly in this region due to similar market developments and rising health care costs. The World Bank data, which was collected in April 2023, indicates that China's health expenditures as a percentage of GDP climbed from 4.98% in 2015 to 5.59% in 2020.
- This report illustrates the most vital attributes of the Biosimilars Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Biosimilars Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Biosimilars Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Biosimilars Market.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. PRODUCT: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Recombinant Non-glycosylated Proteins
5.3. Recombinant Glycosylated Proteins
5.4. Others
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oncology
6.3. Blood Disorders
6.4. Growth Hormonal Deficiency
6.5. Rheumatoid Arthritis
6.6. Chronic and Autoimmune Disorders
6.7. Others
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. AMGEN INC.
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. F HOFFMAN-LA ROCHE LTD.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. SANDOZ INTERNATIONAL GMBH
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. DR. REDDY’S LABORATORIES LTD.
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. PFIZER INC.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. SAMSUNG BIOPIS
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. BIOCON
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. VIATRIS INC.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. CELLTRION HEALTHCARE CO.,LTD.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. ABBVIE INC.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. PFIZER INC.
12. ABBREVIATIONS
Tables
TABLE 1. BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. BIOSIMILARS MARKET VALUE FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. BIOSIMILARS MARKET VALUE FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 5. BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. BIOSIMILARS MARKET VALUE FOR GROWTH HORMONAL DEFICIENCY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. BIOSIMILARS MARKET VALUE FOR RHEUMATOID ARTHRITIS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. BIOSIMILARS MARKET VALUE FOR CHRONIC AND AUTOIMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 13. U.S BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. U.S BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. CANADA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 16. CANADA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 17. MEXICO BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 18. MEXICO BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 19. EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 20. EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. EUROPE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 22. GERMANY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. GERMANY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. U.K BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 25. U.K BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. FRANCE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. FRANCE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. ITALY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 29. ITALY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 30. SPAIN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. SPAIN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 32. ROE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. ROE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 35. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. CHINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 38. CHINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. INDIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 40. INDIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 41. JAPAN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. JAPAN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. REST OF APAC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 44. REST OF APAC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 47. BRAZIL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 48. BRAZIL BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 49. ARGENTINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 50. ARGENTINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 54. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 55. UAE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. UAE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 57. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. AMGEN INC. : FINANCIALS
TABLE 60. AMGEN INC. : PRODUCTS & SERVICES
TABLE 61. AMGEN INC. : RECENT DEVELOPMENTS
TABLE 62. F HOFFMAN-LA ROCHE LTD.: FINANCIALS
TABLE 63. F HOFFMAN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 64. F HOFFMAN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 65. SANDOZ INTERNATIONAL GMBH: FINANCIALS
TABLE 66. SANDOZ INTERNATIONAL GMBH: PRODUCTS & SERVICES
TABLE 67. SANDOZ INTERNATIONAL GMBH: RECENT DEVELOPMENTS
TABLE 68. DR. REDDY’S LABORATORIES LTD.: FINANCIALS
TABLE 69. DR. REDDY’S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 70. DR. REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 71. PFIZER INC.: FINANCIALS
TABLE 72. PFIZER INC.: PRODUCTS & SERVICES
TABLE 73. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 74. SAMSUNG BIOPIS: FINANCIALS
TABLE 75. SAMSUNG BIOPIS: PRODUCTS & SERVICES
TABLE 76. SAMSUNG BIOPIS: RECENT DEVELOPMENTS
TABLE 77. BIOCON: FINANCIALS
TABLE 78. BIOCON: PRODUCTS & SERVICES
TABLE 79. BIOCON: DEVELOPMENTS
TABLE 80. VIATRIS INC.: FINANCIALS
TABLE 81. VIATRIS INC.: PRODUCTS & SERVICES
TABLE 82. VIATRIS INC.: RECENT DEVELOPMENTS
TABLE 83. CELLTRION HEALTHCARE CO.,LTD.: FINANCIALS
TABLE 84. CELLTRION HEALTHCARE CO.,LTD.: PRODUCTS & SERVICES
TABLE 85. CELLTRION HEALTHCARE CO.,LTD.: RECENT DEVELOPMENTS
TABLE 86. ABBVIE INC.: FINANCIALS
TABLE 87. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 88. ABBVIE INC.: RECENT DEVELOPMENTS
Charts
CHART. 1. BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 2. BIOSIMILARS MARKET VALUE FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
CHART. 3. BIOSIMILARS MARKET VALUE FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 5. BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 6. BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 7. BIOSIMILARS MARKET VALUE FOR GROWTH HORMONAL DEFICIENCY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 8. BIOSIMILARS MARKET VALUE FOR RHEUMATOID ARTHRITIS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 9. BIOSIMILARS MARKET VALUE FOR CHRONIC AND AUTOIMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 11. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 12. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 13. U.S BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 14. U.S BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 15. CANADA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 16. CANADA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 17. MEXICO BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 18. MEXICO BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 19. EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 20. EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 21. EUROPE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 22. GERMANY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 23. GERMANY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 24. U.K BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 25. U.K BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 26. FRANCE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 27. FRANCE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 28. ITALY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 29. ITALY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 30. SPAIN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 31. SPAIN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 32. ROE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 33. ROE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 34. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 35. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 36. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 37. CHINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 38. CHINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 39. INDIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 40. INDIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 41. JAPAN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 42. JAPAN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 43. REST OF APAC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 44. REST OF APAC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 45. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 46. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 47. BRAZIL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 48. BRAZIL BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 49. ARGENTINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 50. ARGENTINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 51. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 52. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 53. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 54. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 55. UAE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 56. UAE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 57. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 58. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 59. AMGEN INC. : FINANCIALS
CHART. 60. AMGEN INC. : PRODUCTS & SERVICES
CHART. 61. AMGEN INC. : RECENT DEVELOPMENTS
CHART. 62. F HOFFMAN-LA ROCHE LTD.: FINANCIALS
CHART. 63. F HOFFMAN-LA ROCHE LTD.: PRODUCTS & SERVICES
CHART. 64. F HOFFMAN-LA ROCHE LTD.: RECENT DEVELOPMENTS
CHART. 65. SANDOZ INTERNATIONAL GMBH: FINANCIALS
CHART. 66. SANDOZ INTERNATIONAL GMBH: PRODUCTS & SERVICES
CHART. 67. SANDOZ INTERNATIONAL GMBH: RECENT DEVELOPMENTS
CHART. 68. DR. REDDY’S LABORATORIES LTD.: FINANCIALS
CHART. 69. DR. REDDY’S LABORATORIES LTD.: PRODUCTS & SERVICES
CHART. 70. DR. REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS
CHART. 71. PFIZER INC.: FINANCIALS
CHART. 72. PFIZER INC.: PRODUCTS & SERVICES
CHART. 73. PFIZER INC.: RECENT DEVELOPMENTS
CHART. 74. SAMSUNG BIOPIS: FINANCIALS
CHART. 75. SAMSUNG BIOPIS: PRODUCTS & SERVICES
CHART. 76. SAMSUNG BIOPIS: RECENT DEVELOPMENTS
CHART. 77. BIOCON: FINANCIALS
CHART. 78. BIOCON: PRODUCTS & SERVICES
CHART. 79. BIOCON: DEVELOPMENTS
CHART. 80. VIATRIS INC.: FINANCIALS
CHART. 81. VIATRIS INC.: PRODUCTS & SERVICES
CHART. 82. VIATRIS INC.: RECENT DEVELOPMENTS
CHART. 83. CELLTRION HEALTHCARE CO.,LTD.: FINANCIALS
CHART. 84. CELLTRION HEALTHCARE CO.,LTD.: PRODUCTS & SERVICES
CHART. 85. CELLTRION HEALTHCARE CO.,LTD.: RECENT DEVELOPMENTS
CHART. 86. ABBVIE INC.: FINANCIALS
CHART. 87. ABBVIE INC.: PRODUCTS & SERVICES
CHART. 88. ABBVIE INC.: RECENT DEVELOPMENTS
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. PRODUCT: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Recombinant Non-glycosylated Proteins
5.3. Recombinant Glycosylated Proteins
5.4. Others
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oncology
6.3. Blood Disorders
6.4. Growth Hormonal Deficiency
6.5. Rheumatoid Arthritis
6.6. Chronic and Autoimmune Disorders
6.7. Others
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. AMGEN INC.
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. F HOFFMAN-LA ROCHE LTD.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. SANDOZ INTERNATIONAL GMBH
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. DR. REDDY’S LABORATORIES LTD.
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. PFIZER INC.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. SAMSUNG BIOPIS
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. BIOCON
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. VIATRIS INC.
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. CELLTRION HEALTHCARE CO.,LTD.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. ABBVIE INC.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. PFIZER INC.
12. ABBREVIATIONS
Tables
TABLE 1. BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. BIOSIMILARS MARKET VALUE FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. BIOSIMILARS MARKET VALUE FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 5. BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. BIOSIMILARS MARKET VALUE FOR GROWTH HORMONAL DEFICIENCY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. BIOSIMILARS MARKET VALUE FOR RHEUMATOID ARTHRITIS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. BIOSIMILARS MARKET VALUE FOR CHRONIC AND AUTOIMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 13. U.S BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. U.S BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. CANADA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 16. CANADA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 17. MEXICO BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 18. MEXICO BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 19. EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 20. EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. EUROPE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 22. GERMANY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. GERMANY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. U.K BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 25. U.K BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. FRANCE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. FRANCE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. ITALY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 29. ITALY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 30. SPAIN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. SPAIN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 32. ROE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. ROE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 35. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. CHINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 38. CHINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. INDIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 40. INDIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 41. JAPAN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. JAPAN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. REST OF APAC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 44. REST OF APAC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 47. BRAZIL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 48. BRAZIL BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 49. ARGENTINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 50. ARGENTINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 54. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 55. UAE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. UAE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 57. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. AMGEN INC. : FINANCIALS
TABLE 60. AMGEN INC. : PRODUCTS & SERVICES
TABLE 61. AMGEN INC. : RECENT DEVELOPMENTS
TABLE 62. F HOFFMAN-LA ROCHE LTD.: FINANCIALS
TABLE 63. F HOFFMAN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 64. F HOFFMAN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 65. SANDOZ INTERNATIONAL GMBH: FINANCIALS
TABLE 66. SANDOZ INTERNATIONAL GMBH: PRODUCTS & SERVICES
TABLE 67. SANDOZ INTERNATIONAL GMBH: RECENT DEVELOPMENTS
TABLE 68. DR. REDDY’S LABORATORIES LTD.: FINANCIALS
TABLE 69. DR. REDDY’S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 70. DR. REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 71. PFIZER INC.: FINANCIALS
TABLE 72. PFIZER INC.: PRODUCTS & SERVICES
TABLE 73. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 74. SAMSUNG BIOPIS: FINANCIALS
TABLE 75. SAMSUNG BIOPIS: PRODUCTS & SERVICES
TABLE 76. SAMSUNG BIOPIS: RECENT DEVELOPMENTS
TABLE 77. BIOCON: FINANCIALS
TABLE 78. BIOCON: PRODUCTS & SERVICES
TABLE 79. BIOCON: DEVELOPMENTS
TABLE 80. VIATRIS INC.: FINANCIALS
TABLE 81. VIATRIS INC.: PRODUCTS & SERVICES
TABLE 82. VIATRIS INC.: RECENT DEVELOPMENTS
TABLE 83. CELLTRION HEALTHCARE CO.,LTD.: FINANCIALS
TABLE 84. CELLTRION HEALTHCARE CO.,LTD.: PRODUCTS & SERVICES
TABLE 85. CELLTRION HEALTHCARE CO.,LTD.: RECENT DEVELOPMENTS
TABLE 86. ABBVIE INC.: FINANCIALS
TABLE 87. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 88. ABBVIE INC.: RECENT DEVELOPMENTS
Charts
CHART. 1. BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 2. BIOSIMILARS MARKET VALUE FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY , 2021-2030 (USD BILLION)
CHART. 3. BIOSIMILARS MARKET VALUE FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 5. BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 6. BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 7. BIOSIMILARS MARKET VALUE FOR GROWTH HORMONAL DEFICIENCY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 8. BIOSIMILARS MARKET VALUE FOR RHEUMATOID ARTHRITIS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 9. BIOSIMILARS MARKET VALUE FOR CHRONIC AND AUTOIMMUNE DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 11. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 12. NORTH AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 13. U.S BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 14. U.S BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 15. CANADA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 16. CANADA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 17. MEXICO BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 18. MEXICO BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 19. EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 20. EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 21. EUROPE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 22. GERMANY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 23. GERMANY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 24. U.K BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 25. U.K BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 26. FRANCE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 27. FRANCE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 28. ITALY BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 29. ITALY BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 30. SPAIN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 31. SPAIN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 32. ROE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 33. ROE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 34. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 35. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 36. ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 37. CHINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 38. CHINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 39. INDIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 40. INDIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 41. JAPAN BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 42. JAPAN BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 43. REST OF APAC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 44. REST OF APAC BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 45. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 46. LATIN AMERICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 47. BRAZIL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 48. BRAZIL BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 49. ARGENTINA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 50. ARGENTINA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 51. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 52. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 53. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 54. SAUDI ARABIA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 55. UAE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 56. UAE BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 57. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
CHART. 58. REST OF MIDDLE EAST AND AFRICA BIOSIMILARS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 59. AMGEN INC. : FINANCIALS
CHART. 60. AMGEN INC. : PRODUCTS & SERVICES
CHART. 61. AMGEN INC. : RECENT DEVELOPMENTS
CHART. 62. F HOFFMAN-LA ROCHE LTD.: FINANCIALS
CHART. 63. F HOFFMAN-LA ROCHE LTD.: PRODUCTS & SERVICES
CHART. 64. F HOFFMAN-LA ROCHE LTD.: RECENT DEVELOPMENTS
CHART. 65. SANDOZ INTERNATIONAL GMBH: FINANCIALS
CHART. 66. SANDOZ INTERNATIONAL GMBH: PRODUCTS & SERVICES
CHART. 67. SANDOZ INTERNATIONAL GMBH: RECENT DEVELOPMENTS
CHART. 68. DR. REDDY’S LABORATORIES LTD.: FINANCIALS
CHART. 69. DR. REDDY’S LABORATORIES LTD.: PRODUCTS & SERVICES
CHART. 70. DR. REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS
CHART. 71. PFIZER INC.: FINANCIALS
CHART. 72. PFIZER INC.: PRODUCTS & SERVICES
CHART. 73. PFIZER INC.: RECENT DEVELOPMENTS
CHART. 74. SAMSUNG BIOPIS: FINANCIALS
CHART. 75. SAMSUNG BIOPIS: PRODUCTS & SERVICES
CHART. 76. SAMSUNG BIOPIS: RECENT DEVELOPMENTS
CHART. 77. BIOCON: FINANCIALS
CHART. 78. BIOCON: PRODUCTS & SERVICES
CHART. 79. BIOCON: DEVELOPMENTS
CHART. 80. VIATRIS INC.: FINANCIALS
CHART. 81. VIATRIS INC.: PRODUCTS & SERVICES
CHART. 82. VIATRIS INC.: RECENT DEVELOPMENTS
CHART. 83. CELLTRION HEALTHCARE CO.,LTD.: FINANCIALS
CHART. 84. CELLTRION HEALTHCARE CO.,LTD.: PRODUCTS & SERVICES
CHART. 85. CELLTRION HEALTHCARE CO.,LTD.: RECENT DEVELOPMENTS
CHART. 86. ABBVIE INC.: FINANCIALS
CHART. 87. ABBVIE INC.: PRODUCTS & SERVICES
CHART. 88. ABBVIE INC.: RECENT DEVELOPMENTS
